In 1013 adults aged 18–65 with primary progressive MS and EDSS 3·0–8·0, ocrelizumab vs placebo reduced 12-week confirmed disability progression (hand function or EDSS): 33% vs 40% (HR 0·70, 95% CI 0·57–0·86). Infections 48% vs 45%; serious events similar.
RCTn = 1,013
Giovannoni et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study